Indivior Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Indivior Pharmaceuticals, Inc. en bref

Indivior Pharmaceuticals, Inc. (INDV) is currently trading at 33,39 € with a market capitalization of 3,9 Md €. The trailing P/E ratio stands at 19.64x, with a forward P/E of 9.77x. The 52-week range spans from 11,73 € to 35,74 €; the current price is 6.6% below the yearly high. Year-over-year revenue growth stands at +19.2%. The net profit margin stands at 19.53%.

💰 Dividende

Indivior Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Indivior Pharmaceuticals, Inc. (INDV) au consensus : None. L'objectif de cours moyen est de 44,90 €, soit un potentiel de +34.46% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 41,84 € à 51,43 €.

Indivior Pharmaceuticals, Inc. : la thèse d'investissement en détail

Indivior Pharmaceuticals, Inc. (INDV) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 19.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 82% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 84.96%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Short interest sits at 12.72% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The forward P/E of 9.77x is meaningfully below the trailing 19.64x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 90.2% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
• The analyst consensus price target implies 34.46% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (12.72%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Indivior Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.